Staff Reports
The Food and Drug Administration just cleared another over‑the‑counter naloxone nasal spray. This time it’s REXTOVY, a 4 mg product made by Amphastar Pharmaceuticals. The approval expands the number of naloxone nasal sprays Americans can buy without a prescription — a move the FDA says will save lives. Whether it actually drives down prices or reaches the people who need it most remains to be seen.
What the FDA approved
The FDA approved REXTOVY as an over‑the‑counter naloxone nasal spray for reversing opioid overdoses. Amphastar wins the third slot in the OTC naloxone market, after Narcan and RiVive. The agency put its weight behind clear, pictorial instructions on the box — five steps, including calling 911 after you give a dose — and warned that people revived with naloxone may be shaky, sweaty, nauseous or angry.
Why this matters — and why it won’t fix the whole problem
Naloxone can stop an overdose in minutes when given quickly. With fentanyl driving so many deaths, having naloxone on a shelf at a pharmacy, convenience store or online can mean the difference between life and death. Still, naloxone is an emergency tool, not a cure. It doesn’t treat addiction or stop dealers from flooding communities with fentanyl. The FDA even warned that naloxone can trigger withdrawal in opioid‑dependent people and stressed that 911 should be called after use.
Price, competition, and the politics of access
Here’s the messy bit: the prescription version of REXTOVY has shown up on price trackers in the $44–$63 range per two‑spray box. The OTC price is set by the maker and retailers — and could be higher or lower. The FDA argues more OTC options will spur competition and lower costs. That’s the theory. Nonprofit makers have pushed low‑cost options before, and a real, functioning market would reward that. But without competitive pricing or deliberate distribution plans to reach rural and poor neighborhoods, an OTC label alone won’t make naloxone affordable for many who need it. The FDA even framed this move inside the White House Great American Recovery Initiative — yes, the administration wants wins here — but outcomes will depend on markets, not press releases.
So yes, more naloxone on store shelves is a good thing. But let’s be clear: buying your way out of the opioid crisis is not a policy plan. If Washington insists on approving products and patting itself on the back, it should at least push for real price competition, bulk distribution to community programs, and funding for treatment and recovery. Otherwise we’ll have plenty of naloxone in nice packages and the same old headlines about fentanyl rolling through American towns. That’s not progress — it’s optics.
